Related references
Note: Only part of the references are listed.Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
Catherine C. Smith et al.
BLOOD (2013)
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
C. Albers et al.
LEUKEMIA (2013)
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186
David A. Macdonald et al.
LEUKEMIA & LYMPHOMA (2013)
Molecular analysis of different FLT3-ITD mutations in acute myeloid leukemia
Olga Blau et al.
LEUKEMIA & LYMPHOMA (2013)
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITDAML
Amy Sexauer et al.
BLOOD (2012)
The Origin and Evolution of Mutations in Acute Myeloid Leukemia
John S. Welch et al.
CELL (2012)
Patient-specific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia
Joanna Schiller et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Diversity of the juxtamembrane and TKD1 mutations (Exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data
Susanne Schnittger et al.
GENES CHROMOSOMES & CANCER (2012)
Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia
Aziz Nazha et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm-Combined Prospective Analysis by the German AML Intergroup
Thomas Buechner et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
R. M. Stone et al.
LEUKEMIA (2012)
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
S. K. Metzelder et al.
LEUKEMIA (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single Institution
Amy E. DeZern et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with Sorafenib
Manish Sharma et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
Takashi Sato et al.
BLOOD (2011)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors
Amanda Parmar et al.
CANCER RESEARCH (2011)
Survey of Activated FLT3 Signaling in Leukemia
Ting-lei Gu et al.
PLOS ONE (2011)
Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells
Friedrich Stoelzel et al.
ANNALS OF HEMATOLOGY (2010)
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
Keith W. Pratz et al.
BLOOD (2010)
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience
Lionel Ades et al.
BLOOD (2010)
FLT3 as a therapeutic target in AML: still challenging after all these years
Thomas Kindler et al.
BLOOD (2010)
Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor
M. Michael et al.
BRITISH JOURNAL OF CANCER (2010)
Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prevalence and Prognostic Significance of FLT3 Gene Mutations in Patients with Acute Leukaemia: Analysis of Patients from the Shanghai Leukaemia Co-operative Group
W. Wang et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2010)
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study
Michael Crump et al.
LEUKEMIA & LYMPHOMA (2010)
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response
Keith W. Pratz et al.
BLOOD (2009)
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
Sabine Kayser et al.
BLOOD (2009)
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar et al.
BLOOD (2009)
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
Stephan Metzelder et al.
BLOOD (2009)
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML
Frank Breitenbuecher et al.
BLOOD (2009)
FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
Nikolas von Bubnoff et al.
CANCER RESEARCH (2009)
Mechanisms of resistance to FLT3 inhibitors
S. Haihua Chu et al.
DRUG RESISTANCE UPDATES (2009)
Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers
Nancy L. Lewis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Mechanism-Based Population Pharmacokinetic Model for Characterizing Time-Dependent Pharmacokinetics of Midostaurin and its Metabolites in Human Subjects
Ophelia Q. P. Yin et al.
CLINICAL PHARMACOKINETICS (2008)
Mutant FLT3:: A direct target of sorafenib in acute myelogenous leukemia
Weiguo Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia
A. Agarwal et al.
LEUKEMIA (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
Rosemary E. Gale et al.
BLOOD (2008)
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications
Susan P. Whitman et al.
BLOOD (2008)
BH3 mimetics to improve cancer therapy; mechanisms and examples
Lin Zhang et al.
DRUG RESISTANCE UPDATES (2007)
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations
Rama Krishna Kancha et al.
EXPERIMENTAL HEMATOLOGY (2007)
Flt3-dependent transformation by inactivating c-Cbl mutations in AML
Buelent Sargin et al.
BLOOD (2007)
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia:: A Cancer and Leukemia Group B study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts
T. M. Kohl et al.
LEUKEMIA (2007)
Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential
Sridhar Vempati et al.
BLOOD (2007)
A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old
G. Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment
Cornelius Miething et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells:: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors
Emilio Siendones et al.
HEMATOLOGICAL ONCOLOGY (2007)
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways
Obdulio Piloto et al.
BLOOD (2007)
Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML
Martin Bornhaeuser et al.
BLOOD (2007)
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
Daniel J. DeAngelo et al.
BLOOD (2006)
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
Steven Knapper et al.
BLOOD (2006)
The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases
Steven Knapper et al.
BLOOD (2006)
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
Mark Levis et al.
BLOOD (2006)
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment
Yu-Tzu Tai et al.
CANCER RESEARCH (2006)
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
F Heidel et al.
BLOOD (2006)
FLT3 tyrosine kinase inhibitors
M Levis et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia
M Schaich et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
W Fiedler et al.
BLOOD (2005)
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia
K Ozeki et al.
BLOOD (2004)
The structural basis for autoinhibition of FLT3 by the juxtamembrane domain
J Griffith et al.
MOLECULAR CELL (2004)
Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia
J Cools et al.
CANCER RESEARCH (2004)
In vitro studies of a FM inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
M Levis et al.
BLOOD (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518
JJ Clark et al.
BLOOD (2004)
Juxtamembrane autoinhibition in receptor tyrosine kinases
SR Hubbard
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy
J Tiesmeier et al.
LEUKEMIA RESEARCH (2004)
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
BD Smith et al.
BLOOD (2004)
Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor
R Grundler et al.
BLOOD (2003)
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell et al.
BLOOD (2003)
Phase II study of SU5416 - a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor - in patients with refractory myeloproliferative diseases
FJ Giles et al.
CANCER (2003)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm
S Fröhling et al.
BLOOD (2002)
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia:: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse
LY Shih et al.
BLOOD (2002)
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia:: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors
PD Kottaridis et al.
BLOOD (2002)
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia:: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
S Schnittger et al.
BLOOD (2002)
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
E Weisberg et al.
CANCER CELL (2002)
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
M Levis et al.
BLOOD (2002)
A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
M Levis et al.
BLOOD (2001)